| First Author | Davis L | Year | 2000 |
| Journal | J Exp Clin Cancer Res | Volume | 19 |
| Issue | 2 | Pages | 165-7 |
| PubMed ID | 10965813 | Mgi Jnum | J:64611 |
| Mgi Id | MGI:1889703 | Citation | Davis L, et al. (2000) Effect of Withania somnifera on 20-methylcholanthrene induced fibrosarcoma. J Exp Clin Cancer Res 19(2):165-7 |
| abstractText | Administration of an extract from the root of the plant Withania somnifera (20mg/dose/animal i.p) was found to inhibit the 20-methylcholanthrene induced sarcoma development in mice and increase the life span of tumour bearing animals. Administration of Withania could inhibit the lipid peroxide formation (152 nanomoles/mg protein) (P<0.01) compared with control (198 nanomoles/mg protein). Withania could increase the GSH level (7.7 micromoles/mg protein) which was lowered in control tumour bearing animals (3.96 micromoles/mg protein). GST level was also significantly increased (451 micromoles/min/mg protein) (P<0.001) in Withania treated animals compared to control animals (205 micromoles/min/mg protein). All the animals in the control group developed sarcoma by the 80th day of carcinogen administration. Only 3 animals in the Withania treated group developed sarcoma by the 105th day. In control animals the survival rate was 40% but in the Withania treated group the survival rate was 100% after 15 weeks of carcinogen treatment. These results indicate that Withania could inhibit 20-methylcholanthrene induced sarcoma development in mice. |
